Lydia Scarfò

Experts Toby Eyre and Lydia Scarfò discuss the latest updates in CLL treatment, including BTK and BCL2 inhibitor combinations, BTK degraders, and the role of epcoritamab in Richter’s transformation. They explore the trade-off between toxicity and efficacy, potential sequencing strategies, and promising results in heavily pretreated CLL patients, offering insights on future treatments and clinical trials.

Experts discuss the importance of genomic testing in CLL including defining high-risk disease, the significance of TP53 mutations, using genomic testing to identify treatment strategies, challenges in treating double refractory patients, and the potential of novel targeted agents to improve outcomes.

Experts Paolo Ghia, Susan O'Brien, Lydia Scarfò, and Othman Al-Sawaf review exciting updates in chronic lymphocytic leukemia (CLL) from EHA and ICML 2021. They discuss key clinical trials, second-generation BTKs, fixed-duration therapy, depth of response, stopping treatment, retreatment potential, progression-free survival, VTK inhibitors, akylobrutinib vs. britinib, and different CLL treatment regimens.